Very rapid taper of oral corticosteroids soon after initiating anti-IL-5 therapy is not advised due to risk of an asthma flare. Patients should be advised regarding the absolute need to continue existing controller therapies for asthma, including inhaled corticosteroids, long-acting beta agonists, long-acting muscarinic antagonists and leukotriene modifiers.
The American Academy of Allergy, Asthma & Immunology (AAAAI) states that there is no evidence that suggests an immune response to COVID-19 will be impaired in asthma patients treated with anti-IL5 (anti-IL5Ra), anti-IL4/IL13, or anti-IgE medications.